Zymeworks Inc.: DCF model
A discounted-cash-flow model filled in from Zymeworks Inc.'s filings as reported. Change any assumption; the values follow at once.
A tool for your own analysis, not investment advice. It does arithmetic on the figures the company filed and on assumptions you choose; it does not forecast, and the result is only as good as those assumptions. Every formula is on the methodology page.
Market price USD 28.90 on Oct 29, 2026: Closing price the SEC publishes with its fails-to-deliver data (ZYME).
Assumptions: Base case
Change any figure; the values follow at once.
Revenue and margins
From the filings10-K filed Mar 2, 2026
The years between change on a straight line.
From the filingsThe first year starts at Revenue growth a year from FY2022 to FY2025 (3 years), held within -10% to 25%: -36.43% a year; the years after are your assumption.
The years between change on a straight line.
Your figureAverage operating margin, FY2023–FY2025: -149.55%; the years ahead are your assumption.
Tax and reinvestment
Your assumptionThe effective rate cannot be worked out (losses or no tax line): 25% to start with.
Your assumptionNot on file: set equal to capital spending.
From the filingsAverage share of revenue, FY2023–FY2025
Your figureAverage operating working capital (current assets less cash and short-term investments, less current liabilities other than debt) as a share of revenue, FY2023–FY2025
Discount rate
Your assumption1.0 to start with
Your assumption5% to start with
Your assumptionNot on file: the risk-free rate plus 1.5 points.
From the filingsDebt over debt plus market value on Oct 29, 2026
After the last year
Your assumption2.5% to start with.
From value to shares (every case)
Balance sheet of Q3FY2026, Sep 30, 2026 · 10-Q filed Nov 9, 2026
From the filings
From the filings
From the filings
From the filings
Your assumption
From the filingsdiluted, weighted average, Q3FY2026 · 10-Q filed Nov 9, 2026
The three cases
Base case: value per share
Discount rate 10.15%; long-run growth 2.50%. Values as at the end of FY2025.
| Present value of the 5 projected years | −USD 322 M |
|---|---|
| Present value after the last year | −USD 734 M |
| Enterprise value (the whole business) | −USD 1.1 B |
| Less debt | USD 0 |
| Plus cash and short-term investments | USD 100 M |
| Equity value (the shareholders') | −USD 955 M |
| Divided by shares (millions) | 76.3 |
| Value per share | USD -12.52 |
Value per share
USD -12.52
Below zero: with these figures the debt is worth more than the business.
Price USD 28.90 on Oct 29, 2026
Base case: year by year
Millions of USD. The FY2025 column is as reported; the years after are projected. Tax, capital spending and working capital are signed as they add to (+) or take from (−) free cash flow.
| USD millions | FY2025reported | FY2026projected | FY2027projected | FY2028projected | FY2029projected | FY2030projected |
|---|---|---|---|---|---|---|
| Revenue | 106 | 95 | 89 | 85 | 85 | 87 |
| Growth | 38.9% | -10.0% | -6.9% | -3.8% | -0.6% | 2.5% |
| Operating income (EBIT) | −93 | −95 | −89 | −85 | −85 | −87 |
| Operating margin | -87.3% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Tax on operating income | −0 | −0 | −0 | −0 | −0 | |
| Depreciation and amortisation | — | 2.3 | 2.2 | 2.1 | 2.1 | 2.1 |
| Capital spending | −1.5 | −2.3 | −2.2 | −2.1 | −2.1 | −2.1 |
| Change in working capital | 8.5 | 5.2 | 2.7 | 0.4 | −1.7 | |
| Free cash flow to the firm | −113 | −87 | −84 | −83 | −85 | −89 |
| Discount factor | 0.9079 | 0.8242 | 0.7482 | 0.6793 | 0.6167 | |
| Present value | −79 | −69 | −62 | −57 | −55 |
Base case: sensitivity
How the value per share moves when one pair of figures changes and the rest stay as they are.
Discount rate and long-run growth
Value per share in USD; your figures in the outlined middle; green at or above the market price, red below it.
| Discount rate ↓ · Long-run growth → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 8.15% | -15.14 | -16.18 | -17.4 | -18.87 | -20.64 |
| 9.15% | -12.99 | -13.74 | -14.6 | -15.6 | -16.78 |
| 10.15% | -11.33 | -11.89 | -12.52 | -13.25 | -14.08 |
| 11.15% | -10.02 | -10.45 | -10.93 | -11.47 | -12.08 |
| 12.15% | -8.95 | -9.29 | -9.67 | -10.08 | -10.55 |
Revenue growth and operating margin
Value per share in USD; your figures in the outlined middle; green at or above the market price, red below it.
| Growth, every year ↓ · Margin, every year → | −4 pt | −2 pt | ±0 pt | +2 pt | +4 pt |
|---|---|---|---|---|---|
| −4 pt | -10.28 | -10.04 | -9.81 | -9.58 | -9.35 |
| −2 pt | -11.62 | -11.36 | -11.11 | -10.86 | -10.6 |
| ±0 pt | -13.08 | -12.8 | -12.52 | -12.25 | -11.97 |
| +2 pt | -14.67 | -14.37 | -14.07 | -13.76 | -13.46 |
| +4 pt | -16.4 | -16.07 | -15.74 | -15.41 | -15.08 |
Where the figures come from
The statements as reported, in millions of USD; hover a figure for its filing.
| USD millions | FY2025to Dec 31, 2025 | FY2024to Dec 31, 2024 | FY2023to Dec 31, 2023 | FY2022to Dec 31, 2022 | FY2021to Dec 31, 2021 | FY2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 106 | 76 | 76 | 412 | 27 | 39 |
| Growth | 38.9% | 0.4% | -81.6% | 1446.0% | -31.5% | — |
| Operating income | −93 | −137 | −138 | 131 | −216 | −187 |
| Operating margin | -87.3% | -179.7% | -181.6% | 31.6% | -808.2% | -481.3% |
| Effective tax rate | — | — | — | 8.1% | — | — |
| D&A, % of revenue | — | — | — | — | — | — |
| Capital spending, % of revenue | 1.4% | 2.6% | 3.3% | 2.0% | 46.5% | 11.1% |
| Working capital, % of revenue | 156.0% | 191.4% | -22.6% | -10.5% | -135.8% | — |
| Free cash flow to the firm | −113 | −302 | −167 | 119 | — | — |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
- No debt is tagged on the balance sheet of Q3FY2026: debt starts at zero.
- From the filings: revenue, margins, tax rate, depreciation, capital spending and working capital (fiscal years above), debt, cash, leases and minority interests (balance sheet of Q3FY2026), and the share count (Q3FY2026).
- Market data: US Treasury daily par yield curve, 10-year (Nov 13, 2026); Market price USD 28.90 on Oct 29, 2026: Closing price the SEC publishes with its fails-to-deliver data (ZYME).
- Your assumptions: the growth path and margins ahead, beta, the equity risk premium, long-run growth or the exit multiple, and the weights of the cases. How each figure is worked out: methodology.